Immix Biopharma Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Immix Biopharma Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- LOS Angeles
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IMMX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001873835
- EIN
- 45-4869378
Board of directors
-
Carey Ng · DirectorSince 2023
-
Gabriel S. Morris · Director · CFO, PresidentSince 2023
-
Helen C. Adams · DirectorSince 2023
-
Ilya M. Rachman · Director · CEO and ChairmanSince 2023
-
Jason Hsu · DirectorSince 2023
- Since 2023
-
Melissa Jane Buchan · DirectorSince 2023
-
Nancy T. Chang · DirectorSince 2025
-
Yekaterina Chudnovsky · DirectorSince 2023
Chief executives
Ilya M. Rachman
· CEO and Chairman
Dates unknown
Director election results
Annual meeting of May 22, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.8%
-
99.5%
-
99.6%
-
99.7%
-
99.7%
-
99.7%
-
99.9%
-
100.0%
Board connections
4 of this board's directors also sit on 7 other boards.
- via Magda Marquet
- via Magda Marquet
- via Yekaterina Chudnovsky
- via Magda Marquet
- via Melissa Jane Buchan
- via Magda Marquet
- via Nancy T. Chang
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $10,042
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 22, 2026 | Carey Ng Director | Grant or award | +6,250 | — | — |
| May 22, 2026 | Helen C. Adams Director | Grant or award | +6,250 | — | — |
| May 22, 2026 | Magda Marquet Director | Grant or award | +6,250 | — | — |
| May 22, 2026 | Nancy T. Chang Director | Grant or award | +6,250 | — | — |
| May 22, 2026 | Yekaterina Chudnovsky Director | Grant or award | +6,250 | — | — |
| May 22, 2026 | Melissa Jane Buchan Director | Grant or award | +6,250 | — | — |
| May 22, 2026 | Jason Hsu Director | Grant or award | +6,250 | — | — |
| Dec 10, 2025 | Ilya M. Rachman Director, Officer (CEO and Chairman) | Open-market purchase | +746 | $6.67 | $4,976 |
| Dec 10, 2025 | Gabriel S. Morris Director, Officer (CFO) | Open-market purchase | +770 | $6.58 | $5,067 |
| Dec 8, 2025 | Gabriel S. Morris Director, Officer (CFO) | In-the-money exercise | +156,000 | $0.80 | $124,800 |
| Sep 17, 2025 | Ilya M. Rachman Director, Officer (CEO and Chairman) | Open-market purchase | +2,500 | $2.02 | $5,050 |
| Sep 16, 2025 | Gabriel S. Morris Director, Officer (CFO) | Open-market purchase | +2,600 | $1.97 | $5,122 |
| Jun 18, 2025 | Ilya M. Rachman Director, Officer (CEO and Chairman) | Open-market purchase | +2,178 | $2.30 | $5,009 |
| Jun 18, 2025 | Gabriel S. Morris Director, Officer (CFO) | Open-market purchase | +2,225 | $2.28 | $5,073 |
| Dec 23, 2024 | Jason Hsu Director | Open-market purchase | +40,000 | $2.19 | $87,600 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.